Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean.
Hugo ChaumontNicolas BérardJean-Pierre KaramQuentin LobjoisBenoit TressieresAissatou SignateAnnie LannuzelPhilippe CabrePublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
MiTX is an effective and safe treatment for most of our patients, drastically less expensive than new molecules, and could be allowed in NMOSD Afro-descendant patients in geographical areas where access to care is difficult.